China approves string of ‘telepathy’ devices amid push to leapfrog Elon Musk
Chinese health regulators have approved a series of brain-technology products this year, as domestic startups aim to advance treatment for conditions like paraplegia, Alzheimer’s, and depression. These approvals support Beijing’s goal to lead the world in brain-computer interfaces (BCIs), which enable patients to control digital devices through thought. One such approved system, developed by Tiankai Suishi (Tianjin) Intelligent Technology, helps doctors assess cognitive function using an electrode-studded cap. The company, founded in 2023 with 10.67 million yuan (US$1.59 million) in registered capital, is also seeking approval for a depression diagnosis product.
China’s recent approvals for brain-technology products reflect a concerted national effort to establish leadership in brain-computer interfaces (BCIs), directly challenging companies like Elon Musk’s Neuralink. This is not merely about individual product launches; it is a policy-driven push, with Beijing offering substantial support to domestic firms. The focus extends beyond treatment to early diagnosis, as seen with Tiankai Suishi’s approved system for cognitive function assessment and its efforts in Alzheimer’s and depression diagnostics. For Asia, this development points to China’s ambition to dominate a critical emerging technology sector. The rapid regulatory approvals and state backing create a competitive environment that could accelerate BCI innovation within China. The thing to watch is how quickly these domestically approved technologies move from clinical application to broader market penetration, and whether they can indeed surpass current global benchmarks in efficacy and safety, particularly given Tiankai Suishi’s founding in 2023 and its rapid regulatory success.
